Omnicell Operating Income Over Time
| OMCL Stock | USD 41.37 1.22 3.04% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Omnicell Performance and Omnicell Correlation. Is Health Care Technology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Omnicell. Anticipated expansion of Omnicell directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Omnicell assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth (0.36) | Earnings Share 0.04 | Revenue Per Share | Quarterly Revenue Growth 0.023 | Return On Assets |
Understanding Omnicell requires distinguishing between market price and book value, where the latter reflects Omnicell's accounting equity. The concept of intrinsic value - what Omnicell's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Omnicell's price substantially above or below its fundamental value.
It's important to distinguish between Omnicell's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Omnicell should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Omnicell's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Operating Income Analysis
Compare Omnicell and related stocks such as Progyny, Schrodinger, and Omada Health Common Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PGNY | (11 M) | (11 M) | (11 M) | (11 M) | (11 M) | (11 M) | (11 M) | (11 M) | (3.5 M) | 9.7 M | 8.3 M | 32.3 M | 23.3 M | 62.2 M | 67.5 M | 77.6 M | 81.5 M |
| SDGR | (19 M) | (19 M) | (19 M) | (19 M) | (19 M) | (19 M) | (19 M) | (19 M) | (28 M) | (38.7 M) | (60.9 M) | (111.4 M) | (146.8 M) | (177.4 M) | (209.3 M) | (166.9 M) | (175.2 M) |
| OMDA | (72.3 M) | (72.3 M) | (72.3 M) | (72.3 M) | (72.3 M) | (72.3 M) | (72.3 M) | (72.3 M) | (72.3 M) | (72.3 M) | (72.3 M) | (72.3 M) | (72.3 M) | (66 M) | (43.7 M) | (50.2 M) | (52.7 M) |
| TDOC | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (15.2 M) | (55.8 M) | (62.7 M) | (75.4 M) | (70.9 M) | (80.4 M) | (506.4 M) | (265.6 M) | (13.2 B) | (248.6 M) | (1 B) | (263 M) | (276.1 M) |
| TXG | (18.4 M) | (18.4 M) | (18.4 M) | (18.4 M) | (18.4 M) | (18.4 M) | (18.4 M) | (18.4 M) | (110.8 M) | (29.1 M) | (85.3 M) | (52.9 M) | (167.9 M) | (265.3 M) | (194.6 M) | (110.9 M) | (116.4 M) |
| PHR | (14.6 M) | (14.6 M) | (14.6 M) | (14.6 M) | (14.6 M) | (14.6 M) | (14.6 M) | (14.6 M) | (9.5 M) | (15.3 M) | (25.7 M) | (116.8 M) | (176.6 M) | (136.5 M) | (58.1 M) | (52.3 M) | (54.9 M) |
| UFPT | 1.3 M | 15.7 M | 16.7 M | 17.4 M | 11.6 M | 11.7 M | 12.2 M | 11.7 M | 19.6 M | 24.7 M | 16.7 M | 21.2 M | 55.4 M | 57.7 M | 80.9 M | 92.3 M | 97 M |
| ASTH | (5 K) | (413.3 K) | (2.1 M) | (3.9 M) | (694.3 K) | (6.6 M) | (10.5 M) | 37.6 M | 92.2 M | 32.4 M | 6.1 M | 98.2 M | 104.3 M | 84.6 M | 89.3 M | 102.8 M | 107.9 M |
| SSII | (66.0) | (66.0) | (66.0) | (66.0) | (66.0) | (66.0) | (462.5 K) | (1 M) | (960.4 K) | (3.3 M) | (1.1 M) | (1.4 M) | (5.7 M) | (20.7 M) | (19 M) | (17.1 M) | (16.2 M) |
| GDRX | 18.9 M | 18.9 M | 18.9 M | 18.9 M | 18.9 M | 18.9 M | 18.9 M | 50.3 M | 77.3 M | 139.7 M | (275.7 M) | 13.4 M | 1.7 M | (27 M) | 65.8 M | 87.5 M | 91.9 M |
Omnicell and related stocks such as Progyny, Schrodinger, and Omada Health Common Operating Income description
Operating Income is the amount of profit realized from Omnicell operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Omnicell is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Omnicell | OMCL |
Specialization | Health Care, Health Care Equipment & Services |
| Business Address | 4220 North Freeway, |
| Exchange | NASDAQ Exchange |
USD 41.37
Check out Omnicell Performance and Omnicell Correlation. For more information on how to buy Omnicell Stock please use our How to buy in Omnicell Stock guide.You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Omnicell technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.